The new drug prospect (GLP-1/ tesaglitazar) enhanced improvements of body weight, food consumption, and glucose metabolism relative to the GLP-1 or tesaglitazar alone in overweight male mice. Credit: Helmholtz Munich.
Nevertheless, in order to make use of the drug therapeutically, the scientists utilized a technique: they biochemically integrated tesaglitazar with the gastrointestinal hormone GLP-1. As an outcome, the integrated drug can only deal with cells and tissues that have GLP-1 receptors.
” This trick allowed us to integrate the blood sugar-reducing effects of GLP-1 and tesaglitazar into a single extremely efficient molecule while keeping tesaglitazar away from tissues that it might damage,” explains PD Dr. Timo Müller, matching author, director of the Institute of Diabetes and Obesity, and scientist at DZD.
The brand-new drug improves glucose tolerance and sugar metabolism.
The new drug has currently been successfully tested in animal studies: “The sugar metabolic process of diabetic and obese male mice improved to a far greater level compared to treatment using just the GLP-1 hormone or tesaglitazar alone– and without any damaging adverse results to the liver or kidney,” states Professor Kerstin Stemmer, one of the lead authors of the research study.
The compound was especially reliable in increasing glucose tolerance levels. Only minimal dosages of the new drug were needed to attain sustainable enhancement of glucose metabolism.
” This drug has great potential for the severe treatment of raised blood sugar level levels associated with type 2 diabetes,” states Aaron Novikoff, another lead author of the study.
The researchers now wish to examine whether this drug likewise has the possible to deal with human beings with type 2 diabetes and whether the effectiveness of this new combination treatment can be optimized even more utilizing biochemical modifications.
Background:.
The team comprised of Professor Dr. Matthias Tschöp (scientific director of Helmholtz Munich), PD Dr. Timo Müller, Richard DiMarchi, Ph.D. (Indiana University), and Dr. Brian Finan (Novo Nordisk) has actually been working for several years on new drug candidates for the treatment of type 2 diabetes and weight problems. Poly-agonists concurrently imitate the impacts of different hormones. Medical trials have shown that some poly-agonists are incredibly promising in the treatment of weight problems and type 2 diabetes and are already in stage 2 and phase 3 trials.
This year in the USA the first dual agonist drug for the treatment of type 2 diabetes was approved. The drug combines GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonists that mimic the impacts of the digestive hormones GLP-1 and GIP.
Recommendation: “GLP-1-mediated shipment of tesaglitazar enhances weight problems and glucose metabolic process in male mice” by Carmelo Quarta, Kerstin Stemmer, Aaron Novikoff, Bin Yang, Felix Klingelhuber, Alex Harger, Mostafa Bakhti, Aimee Bastidas-Ponce, Eric Baugé, Jonathan E. Campbell, Megan Capozzi, Christoffer Clemmensen, Gustav Collden, Perla Cota, Jon Douros, Daniel J. Drucker, Barent DuBois, Annette Feuchtinger, Cristina Garcia-Caceres, Gerald Grandl, Nathalie Hennuyer, Stephan Herzig, Susanna M. Hofmann, Patrick J. Knerr, Konxhe Kulaj, Fanny Lalloyer, Heiko Lickert, Arek Liskiewicz, Daniela Liskiewicz, Gandhari Maity, Diego Perez-Tilve, Sneha Prakash, Miguel A. Sanchez-Garrido, Qian Zhang, Bart Staels, Natalie Krahmer, Richard D. DiMarchi, Matthias H. Tschöp, Brian Finan, and Timo D. Müller, 22 August 2022, Nature Metabolism.DOI: 10.1038/ s42255-022-00617-6.
The group made up of Professor Dr. Matthias Tschöp (scientific director of Helmholtz Munich), PD Dr. Timo Müller, Richard DiMarchi, Ph.D. (Indiana University), and Dr. Brian Finan (Novo Nordisk) has been working for numerous years on new drug prospects for the treatment of type 2 diabetes and weight problems.
The drug has actually already been successfully tested in animal studies.
Researchers develop a brand-new drug candidate to deal with diabetes.
A novel hormone combination has been developed by a research team from Helmholtz Munich, the German Center for Diabetes Research (DZD), and Novo Nordisk for the prospective treatment of type 2 diabetes in the future. The scientists combined the blood sugar-lowering actions of the medications tesaglitazar and GLP-1 (Glucagon-like peptide-1) to produce a brand-new and incredibly effective drug.
The benefit of combining Tesaglitazar with GLP-1 is that the Tesaglitazar just penetrates the tissue with GLP-1 receptors. Researchers have already effectively checked the new drug in animal research studies.
Tesaglitazar enhances glucose and fat metabolism in type 2 diabetic clients. It increases insulin level of sensitivity by acting on 2 receptors inside the cell nucleus. This was shown in phase 3 scientific trials. Tesaglitazar has side effects such as kidney damage.
The benefit of integrating Tesaglitazar with GLP-1 is that the Tesaglitazar only permeates the tissue with GLP-1 receptors. This increases the impacts on sugar metabolism while decreasing the side impacts of tesaglitazar. Researchers have actually currently successfully checked the brand-new drug in animal research studies. Tesaglitazar has side impacts such as kidney damage.
